Biohaven (NYSE:BHVN) Sees Strong Trading Volume – Still a Buy?

Biohaven Ltd. (NYSE:BHVN) saw strong trading volume on Thursday . Approximately 1,681,234 shares traded hands during trading, a decline of 37% from the previous session’s volume of 2,649,776 shares.The stock last traded at $12.6670 and had previously closed at $15.00.

Key Stories Impacting Biohaven

Here are the key news stories impacting Biohaven this week:

• Negative Sentiment: The FDA paused new patient enrollment in pivotal BHV-7000 trials following findings from rodent studies. The hold raises safety concerns, could delay the development timeline and increases the risk of additional regulatory requirements or changes to the program. Reuters article
• Negative Sentiment: The regulatory setback affects a key late-stage pipeline asset and adds to concerns surrounding Biohaven’s development execution. Analysts and coverage noted that a competing epilepsy drugmaker could benefit if BHV-7000’s progress is delayed. Barron’s article
• Negative Sentiment: Market reports characterized the FDA action as a significant blow, with Biohaven shares falling sharply as investors reassessed the timing, probability of success and potential commercial value of the epilepsy program. MarketScreener article
• Neutral Sentiment: HC Wainwright reaffirmed its “Neutral” rating but reduced or maintained its price target at $10.00, implying roughly 21.6% downside from the cited $12.76 reference price. This signals limited near-term conviction while the regulatory issue is addressed.

Analysts Set New Price Targets

Several research analysts have recently weighed in on BHVN shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biohaven in a research note on Friday, August 28th. Canaccord Genuity Group set a $21.00 price objective on Biohaven in a research note on Friday, August 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Biohaven in a report on Friday, June 26th. Wall Street Zen raised Biohaven from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $30.00 price target on shares of Biohaven in a research report on Wednesday, August 26th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $18.69.

Biohaven Stock Down 0.3%

The company has a market capitalization of $1.93 billion, a PE ratio of -2.75 and a beta of 1.28. The company’s 50 day moving average is $14.73 and its two-hundred day moving average is $12.11. The company has a quick ratio of 4.73, a current ratio of 4.73 and a debt-to-equity ratio of 21.23.

Biohaven (NYSE:BHVN) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.15). On average, analysts anticipate that Biohaven Ltd. will post -3.33 earnings per share for the current year.

Institutional Trading of Biohaven

Hedge funds have recently modified their holdings of the company. PNC Financial Services Group Inc. boosted its position in shares of Biohaven by 113.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock valued at $36,000 after acquiring an additional 1,268 shares during the last quarter. IFP Advisors Inc raised its stake in Biohaven by 55.4% during the fourth quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock valued at $46,000 after purchasing an additional 1,450 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in Biohaven by 178.4% during the fourth quarter. EverSource Wealth Advisors LLC now owns 4,031 shares of the company’s stock valued at $46,000 after purchasing an additional 2,583 shares in the last quarter. Arax Advisory Partners lifted its position in Biohaven by 943.3% during the fourth quarter. Arax Advisory Partners now owns 4,914 shares of the company’s stock valued at $55,000 after purchasing an additional 4,443 shares during the last quarter. Finally, BlueCrest Capital Management Ltd bought a new position in Biohaven during the second quarter valued at $60,000. 88.78% of the stock is owned by hedge funds and other institutional investors.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.